<!DOCTYPE html>
<html>
<meta charset="UTF-8">
<head>
    <title>IL7——IL7R - PMID Details</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            line-height: 1.6;
            color: #333;
        }

        h1 {
            text-align: center;
            font-size: 2.5em;
            color: #2c3e50;
            margin-bottom: 20px;
        }

        /* Navbar Styles */
        nav {
            background-color: #2c3e50;
            padding: 10px 20px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            color: white;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        nav .navbar-left, nav .navbar-right {
            display: flex;
            align-items: center;
        }

        nav a {
            color: white;
            text-decoration: none;
            margin: 0 15px;
            font-size: 1.1em;
            transition: color 0.3s ease;
        }

        nav a:hover {
            color: #f39c12;
        }

        nav .divider {
            color: #ecf0f1;
            margin: 0 10px;
        }

        /* Page Footer */
        footer {
            margin-top: 40px;
            padding: 10px 20px;
            background-color: #f7f7f7;
            color: #333;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        /* Tab and Content Styles */
        .tab {
            display: flex;
            flex-wrap: wrap;
            justify-content: center;
            margin-bottom: 20px;
        }

        .tab button {
            padding: 10px 20px;
            margin: 5px;
            margin-bottom: 10px;
            cursor: pointer;
            background-color: #f4f4f4;
            border: 2px solid #ddd;
            border-radius: 5px;
            font-size: 1.1em;
            transition: background-color 0.3s ease;
            flex-basis: calc(10% - 10px);
            box-sizing: border-box;
        }

        .tab button:hover {
            background-color: #ecf0f1;
        }

        .tab button.active {
            background-color: #3498db;
            color: white;
            border-color: #2980b9;
        }

        .tabcontent {
            display: none;
            padding: 20px;
            margin-top: 10px;
            background-color: #ecf0f1;
            border-radius: 5px;
            box-shadow: 0px 0px 10px rgba(0, 0, 0, 0.1);
        }

        .tabcontent.active {
            display: block;
        }

        .tabcontent h2 {
            font-size: 2em;
            color: #2980b9;
        }

        .tabcontent p {
            font-size: 1.2em;
            line-height: 1.8;
        }

        /* Emphasize Title and Abstract */
        .title, .abstract {
            background-color: #f9f9f9;
            padding: 20px;
            margin: 10px 0;
            border-left: 5px solid #2980b9;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
        }

        .abstract {
            border-left: 5px solid #e74c3c;
        }
    </style>
    <script>
        function adjustTabStyle() {
            var tabCount = document.querySelectorAll('.tab button').length;
            var tabContainer = document.querySelector('.tab');

            if (tabCount > 10) {
                tabContainer.classList.add('small-tabs');
            }
        }

        function openTab(evt, tabId) {
            document.querySelectorAll(".tabcontent").forEach(tab => tab.style.display = "none");
            document.querySelectorAll(".tablinks").forEach(link => link.classList.remove("active"));
            document.getElementById(tabId).style.display = "block";
            evt.currentTarget.classList.add("active");
        }

        window.onload = adjustTabStyle;
    </script>
</head>
<body>
    <nav>
        <div class="navbar-left">
            <a href="">ConnectomeDB</a>
            <a href="https://comp.med.yokohama-cu.ac.jp/collab/connectomeDB/">Home</a>
            <a href="https://comp.med.yokohama-cu.ac.jp/collab/connectomeDB/database.html">Database</a>
        </div>
        <div class="navbar-right">
            <a href="https://www-user.yokohama-cu.ac.jp/~bioinfo/">YCU Bioinformatics Lab</a>
            <span class="divider">|</span>
            <a href="https://perkins.org.au/research/labs/cancer-program/systems-biology-and-genomics-overview/">Perkins Systems Biology & Genomics Lab</a>
        </div>
    </nav>

    <h1>PMID Details for IL7——IL7R</h1>

    <div class="tab">
        <button class="tablinks active" onclick="openTab(event, 'tab7522165')">7522165</button><button class="tablinks " onclick="openTab(event, 'tab11858939')">11858939</button><button class="tablinks " onclick="openTab(event, 'tab10390077')">10390077</button>
    </div>

    <div class="tabcontent" id="titleTab">
        <div class="title">
            <h2>Title</h2>
            <p>{{TITLE}}</p>
            <i> Journal:{{JOURNAL}}; Year Published:{{YEAR}}</i>   
        </div>
    </div>

    <div class="tabcontent" id="abstractTab">
        <div class="abstract">
            <h2>Abstract</h2>
            <p>{{ABSTRACT}}</p>
        </div>
    </div>

    
                <div id="tab7522165" class="tabcontent active">
                    <h2>Interleukin-7 induces the association of phosphatidylinositol 3-kinase with the alpha chain of the interleukin-7 receptor.</h2>
                    <h3>European journal of immunology; 1994</h3>
                    <p>The recently characterized receptor for interleukin (IL)-7 (IL-7R) includes a unique alpha chain as well as a common gamma chain shared with the receptors for IL-2 and IL-4. Engagement of the IL-7R activates the intracellular enzyme phosphatidylinositol (PtdIns) 3-kinase but the mechanism of PtdIns 3-kinase activation and the molecular basis of its interaction with IL-7R are not known. Here we show that IL-7 causes the 85-kDa regulatory subunit of PtdIns 3-kinase (p85), and PtdIns 3-kinase activity, to associate with the IL-7R. This interaction can be ascribed to ligand-induced phosphorylation of a single Tyr residue in the receptor's unique alpha chain. Herbimycin A, a specific protein tyrosine kinase inhibitor, suppresses not only tyrosine phosphorylation of the IL-7R but also its association with p85. A phosphopeptide corresponding to the sequence surrounding Tyr449 in the cytoplasmic tail of the IL-7R alpha chain, but not its non-phosphorylated analogue or phosphopeptides coincident with the sequences surrounding other alpha chain Tyr residues, efficiently competes out p85 binding. Replacement of Tyr449 with Phe results in a loss of p85 binding. Finally, soluble forms of the src homology 2 domains of p85, which bind directly to phosphotyrosyl peptides, specifically inhibit the association of p85 with the IL-7R. Thus, PtdIns 3-kinase recruitment occurs through a single, phosphotyrosine dependent recognition motif surrounding Tyr449 in the IL-7R alpha chain. This motif corresponds to a canonical sequence for p85 binding, Tyr(P)-X-X-Met. Since the closely related IL-2R and IL-4R also activate PtdIns 3-kinase but are devoid of such canonical motifs, our results suggest that the mechanism by which IL-7R recruits and activates PtdIns 3-kinase differs fundamentally from that used by the other receptors. PtdIns 3-kinase may, therefore, play a unique and important role in the biological response to IL-7.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/7522165/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                
                <div id="tab11858939" class="tabcontent ">
                    <h2>Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines.</h2>
                    <h3>Cellular signalling; 2002</h3>
                    <p>The high-affinity human interleukin-7 (IL-7)R is a heterodimeric complex consisting of the IL-7Ralpha and common interleukin-2 receptor gamma (IL-2Rgamma(c)) chains. Activation of the IL-7R complex is associated with tyrosine and serine residue phosphorylation of a number of intracellular substrates leading to proliferation and induction of various cellular differentiation processes. In this study, we demonstrate, by S1 nuclease protection assay, immunoprecipitation and in vitro kinase assay that functional human (h) IL-7R is expressed in haematopoietic and nonhaematopoietic cell lines. The National Cancer Institute (NCI) tumour panel of 60 cell lines (NCI60) was screened for the expression of IL-7R mRNA by S1 nuclease protection assay, and IL-7R mRNA was detected in 9 of 12 leukemia, 3 of 7 lung, 4 of 6 CNS, 2 of 7 melanoma, 2 of 7 renal, 1 of 6 colon and 1 of 6 breast cancer cell lines. Immunoblot analysis of haematopoietic, lung cancer and brain tumour cell lines demonstrated expression of IL-7R, IL-2Rgamma(c) and p59 fyn, suggesting that the components of an IL-7R signalling network are present in nonhaematopoietic neoplastic cells. Immunoprecipitation of IL-7Ralpha followed by an in vitro kinase assay demonstrated functional receptor phosphorylation events in the lung cancer cells but not in the brain tumour cell lines. The expression of functional IL-7R on epithelial tumour cells may represent a potential target for receptor-directed therapy.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/11858939/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                
                <div id="tab10390077" class="tabcontent ">
                    <h2>Biological and clinical implications of interleukin-7 and lymphopoiesis.</h2>
                    <h3>Cytokines, cellular & molecular therapy; 1999</h3>
                    <p>Interleukin 7 (IL-7) is a stromal cell-derived cytokine that stands out as being the only cytokine identified to date on which development of B and T lymphocytes is absolutely dependent. IL-7 functions primarily as a growth and antiapoptosis factor for B- and T-cell (alphabeta and gammadelta TCR+ cells) precursors, and is essential for differentiation of gammadelta TCR+ cells. IL-7 can function as a cofactor during myelopoiesis, and is capable of activating monocytes/macrophages and natural killer (NK) cells. Its receptor (IL-7R) is a heterodimer of an alpha chain that specifically binds IL-7 and the common gamma chain gammac that is also a component of the receptors for IL-2, IL-4, IL-9 and IL-15. The functions of IL-7 in normal lymphocyte development and activation have led to the demonstration of the ability of IL-7 to stimulate lymphopoiesis in lymphopenic mice, suggesting a possible clinical application of IL-7 in accelerating lymphoid reconstitution in lymphopenic patients. There have also been a number of preclinical studies pointing to the possible utility of IL-7 in antitumor clinical applications, and clinical trials involving IL-7 gene therapy of metastatic disease are underway. IL-7 has also been shown to promote engraftment of stem cells in mice receiving bone marrow transplants, pointing to a possible use of IL-7 in patients receiving bone marrow or peripheral blood stem cell transplants. Areas of IL-7 biology that are essentially unexplored include the mechanisms of regulation of the expression of IL-7 and IL-7Ralpha, as well as the mechanisms by which IL-7 is a growth and differentiation factor for gammadelta T cells but a growth factor only for alphabeta T cells.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/10390077/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                

    <footer>
        <span>© Copyright 2024, YCU Bioinformatics Laboratory</span>
        <span>Page built with <a href="https://quarto.org/">Quarto</a> by バイオインフォマティクス解析センター</span>
    </footer>
</body>
</html>
